18th Annual NATA Symposium
The 18th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Firenze Fiera Congress & Exhibition Center in Florence, Italy, on April 20-21, 2017.
The scientific programme is now online.
The extended deadline for abstract submission is January 15, 2017.
The second announcement can be downloaded here.
For more information, please visit the Events > Annual Symposium section.
More information about the 18th Annual NATA Symposium
Focused Update: Perioperative Management of Jehovah’s Witness Patients in Relation to Their Refusal of Allogeneic Blood Transfusion
Jehovah's Witness (JW) patients strictly refuse allogeneic blood transfusion (red blood cells, plasma and platelets), even in the presence of life-threatening anemia and/or coagulopathy. However, today JW patients can undergo major surgical procedures without facing an excessive risk of death—provided that a prospectively conceived and structured perioperative management is applied.
In a Nataonline Focused Update, Prof. Oliver Habler, Department of Anesthesiology, Surgical Intensive Care Medicine and Pain Therapy, Krankenhaus Nordwest GmbH, Frankfurt, Germany, reviews the perioperative management of JW patients with emphasis on the following cornerstones: (1) the preoperative optimization of cardiopulmonary status and the correction of preoperative anemia and coagulopathy, (2) the perioperative collection of autologous blood, (3) the minimization of perioperative blood loss and (4) the utilization of the organism’s natural tolerance to anemia and its acute accentuation in the case of life-threatening anemia.
Focused update: The management of massive hemorrhage/transfusion in civilian trauma
The management of massive hemorrhage/transfusion in trauma has evolved considerably in the past few years. Based on a consensus established in 2005, several civilian trauma centers have adopted a restrictive approach to the administration of crystalloids in view of minimizing hemodilution, along with the transfusion of red blood cells (RBC), fresh frozen plasma (FFP) and platelet concentrates (PC) in a 1:1:1 ratio. In a Nataonline Focused Update, Professor Jean-François discusses the evidence supporting this strategy.